blinatumomab: Clinical Trials

165 trials of blinatumomab, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

53 recruiting, 31 completed, 25 active not recruiting, 24 not yet recruiting. 102 Phase 2, 43 Phase 1, 28 Phase 3, 12 Not applicable, 3 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 2102Recruiting 34, Completed 21, Active not recruiting 17, Not yet recruiting 13, Terminated 8, Unknown 6, Withdrawn 3
Phase 143Recruiting 13, Completed 11, Active not recruiting 9, Not yet recruiting 4, Withdrawn 3, Unknown 2, Terminated 1
Phase 328Recruiting 12, Active not recruiting 7, Not yet recruiting 4, Completed 3, Terminated 1, Withdrawn 1
Not applicable12Not yet recruiting 5, Recruiting 5, Unknown 2
Phase 43Not yet recruiting 1, Recruiting 1, Terminated 1
Early Phase 11Terminated 1

Follow blinatumomab: new trials by email Literature Review of blinatumomab trials Research Report on blinatumomab

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study Evaluating Subcutaneous Versus Intravenous Blinatumomab in Newly Diagnosed Adults With B-cell Precursor Acute Lymphoblastic Leukaemia
Blinatumomab, HyperCVAD - Philadelphia Chromosome Negative B-cell Precursor Acute Lymphoblastic Leukemia
Phase 3Not yet recruitingAmgen5602028-06-302026-09-15
Asciminib-Based Induction Therapy for the Treatment of Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Asciminib, Biospecimen Collection, Blinatumomab - B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
Phase 1Not yet recruitingCity of Hope Medical Center212027-10-132026-11-03
Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromosome (ph)-Positive and/or BCR::ABL1 Positive Acute Lymphoblastic Leukemia (ALL)
Blinatumomab, olverembatinib - Phase II Clinical Trial, Blinatumomab
Phase 2Not yet recruitingM.D. Anderson Cancer Center602027-01-272026-10-07
A Study of Inotuzumab and Blinatumomab in People With B-cell Acute Lymphoblastic Leukemia
Blinatumomab Injection - B-cell Acute Lymphoblastic Leukemia, B-Cell Acute Lymphoblastic Leukemia, Adult
Phase 1 / Phase 2Not yet recruitingMemorial Sloan Kettering Cancer Center262026-12-012026-11-09
Venetoclax Plus Inotuzumab Reduced-Intensity Induction Sequentially Followed by Blinatumomab in B-ALL
Inotuzumab ozogamicin (INO), Venetoclax (VEN), Vincristine - ALL
Not applicableNot yet recruitingInstitute of Hematology & Blood Diseases Hospital, China432026-11-302026-11-06
Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AML
Fludarabine, Cytarabine, Idarubicin - Myeloid Leukemia
Phase 1 / Phase 2Not yet recruitingM.D. Anderson Cancer Center302026-11-302026-11-02
A Phase IB Trial of Subcutaneous Blinatumomab in Combination With Revumenib for Patients With KMT2A-rearranged Acute Lymphoblastic Leukemia
Revumenib, Blinatumomab - Blinatumomab, Revumenib
Phase 1Not yet recruitingM.D. Anderson Cancer Center202026-11-182026-11-12
Testing Blinatumomab With or Without Revumenib in Patients With B-cell Acute Lymphoblastic Leukemia With a Genetic Change Requiring More Treatment
Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration - Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia
Phase 2Not yet recruitingSWOG Cancer Research Network902026-10-142026-10-13
Immunotargeted Therapy Plus Low-Dose Chemotherapy in Newly Diagnosed Adult Ph+ B-ALL
olverembatinib, Venetoclax, Inotuzumab Ozogamicin (IO) - Ph+ Acute Lymphoblastic Leukemia (Ph+ALL)
Phase 2Not yet recruitingInstitute of Hematology & Blood Diseases Hospital, China222026-10-122026-09-25
Exploratory Study on the Efficacy and Safety of Low-Dose Blinatumomab in the Treatment of Moderate to Severe Primary Sjögren's Syndrome
Blinatumomab, background treatment - Primary Sjögren's Syndrome (pSS)
Phase 2Not yet recruitingBeijing Tongren Hospital122026-09-252026-10-01
International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)
Inotuzumab ozogamicin (INO), Blinatumomab - B-Cell Acute Lymphoblastic Leukaemia
Phase 3RecruitingCharite University, Berlin, Germany7502026-09-012026-10-26
A Study of Injectable BLB101 and Blincyto® in Adult Participants With R/R CD19+ B-ALL
BLB101 for Injection, Blinatumomab for Injection - Precursor B-cell Acute Lymphoblastic Leukemia
Phase 3Not yet recruitingInstitute of Hematology & Blood Diseases Hospital, China2122026-08-092026-07-23
Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)
Asciminib Adult formulation, Asciminib Pediatric formulation, Dexamethasone - Acute Lymphoblastic Leukemia, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive
Phase 1 / Phase 2RecruitingNovartis Pharmaceuticals502026-07-052026-11-12
Immune-targeted Combination With Chemotherapy for Acute Leukemia of Ambiguous Lineage
Blinatumomab, Venetoclax - Adult ALL, MPAL
Not applicableNot yet recruitingInstitute of Hematology & Blood Diseases Hospital, China502026-06-302026-02-11
Efficacy and Safety of Low-Dose Blinatumomab in the Treatment of Refractory Autoimmune Encephalitis and Autoimmune Cerebellitis
Blinatumomab - Autoimmune Encephalitis (AE), Autoimmune Cerebellitis
Phase 4Not yet recruitingBeijing Tiantan Hospital122026-06-242026-07-06
Immuno-Targeted Therapy Plus Low-Dose Chemotherapy for Newly Diagnosed Adult Ph-Negative B-ALL: A Prospective Umbrella Trial
Inotuzumab Ozogamicin (IO), Venetoclax, Blinatumomab - Ph- Acute Lymphoblastic Leukemia (Ph-ALL)
Phase 2Not yet recruitingInstitute of Hematology & Blood Diseases Hospital, China322026-06-122026-06-11
ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL
Olverembatinib, Gecacitinib, Venetoclax - Ph-Like, Acute Lymphoblastic Leukemia
Not applicableRecruitingInstitute of Hematology & Blood Diseases Hospital, China922026-05-302026-05-13
A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)
MK-1045, Blinatumomab, Acetaminophen - B-cell Acute Lymphoblastic Leukemia
Phase 2 / Phase 3RecruitingMerck Sharp & Dohme LLC3402026-05-182026-11-10
Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukemia
Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Blinatumomab - Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia
Phase 1RecruitingCity of Hope Medical Center262026-05-132026-10-16
A Phase 2 Study of Bcl-2 Inhibitor Combined With Azacitidine for Newly Diagnosed Mixed Phenotype Acute Leukemia
BCL-2 indibitor, Azacitidine (AZA), Blinatumomab - Newly Diagnosed Mixed Phenotype Acute Leukemia
Phase 2Not yet recruitingThe First Affiliated Hospital of Soochow University522026-05-012026-05-07

Showing 20 of 165. Sign in to see all of them.

Conditions studied

Precursor Cell Lymphoblastic Leukemia-Lymphoma (74)  ·  Burkitt Lymphoma (44)  ·  Neoplasm, Residual (18)  ·  Recurrence (17)  ·  Leukemia (16)  ·  Leukemia, Biphenotypic, Acute (9)  ·  Lymphoma, Non-Hodgkin (8)  ·  Precursor B-Cell Lymphoblastic Leukemia-Lymphoma (7)  ·  Lymphoproliferative Disorders (6)  ·  Leukemia, Lymphoid (5)  ·  Lymphatic Diseases (5)  ·  Immunoproliferative Disorders (4)  ·  Leukemia, Myelogenous, Chronic, BCR-ABL Positive (4)  ·  Lymphoma (4)  ·  Lymphoma, B-Cell (4)

Sponsors

Amgen (20)  ·  M.D. Anderson Cancer Center (16)  ·  Institute of Hematology & Blood Diseases Hospital, China (14)  ·  National Cancer Institute (NCI) (11)  ·  Amgen Research (Munich) GmbH (7)  ·  The First Affiliated Hospital of Soochow University (7)  ·  St. Jude Children's Research Hospital (6)  ·  Goethe University (4)  ·  Gruppo Italiano Malattie EMatologiche dell'Adulto (4)  ·  City of Hope Medical Center (3)  ·  First Affiliated Hospital of Zhejiang University (3)  ·  Sichuan University (3)  ·  Assistance Publique - Hôpitaux de Paris (2)  ·  Chen Suning (2)  ·  MedImmune LLC (2)

Countries

United States (76)  ·  China (33)  ·  Germany (28)  ·  France (25)  ·  Italy (24)  ·  Australia (19)  ·  Spain (18)  ·  Canada (16)  ·  Austria (13)  ·  Belgium (13)  ·  Netherlands (13)  ·  United Kingdom (13)  ·  Israel (12)  ·  Puerto Rico (10)  ·  Czechia (9)

Top investigators

Elias Jabbour (5)  ·  Elias Jabbour, MD (4)  ·  Nicola Goekbuget, MD (4)  ·  Brandon Triplett, MD (3)  ·  Xiaofan Zhu, MD (3)  ·  Elias J Jabbour, MD (2)  ·  Max Topp, MD (2)  ·  Suning Chen (2)  ·  A.W. Rijneveld, Dr. (1)  ·  Alessandro Rambaldi (1)

Results publications

PMID 41671463, PMID 35622074, PMID 27209293, PMID 22592608, PMID 25192414, PMID 25385737, PMID 25524800, PMID 26755709, PMID 27873237, PMID 27998223, PMID 28533941, PMID 28859185, PMID 28922466, PMID 29352703, PMID 29358182, PMID 30254079, PMID 31648325, PMID 32289160, PMID 32546071, PMID 32589970, PMID 32619115, PMID 33085860, PMID 33191168, PMID 33542479, PMID 33651090, PMID 33844429, PMID 34161631, PMID 34228983, PMID 34914826, PMID 35129146, PMID 35501736, PMID 35503708, PMID 35713551, PMID 35941212, PMID 35982483, PMID 36000952, PMID 36279879, PMID 36322825, PMID 36402146, PMID 37131217, PMID 37141547, PMID 37187201, PMID 37257143, PMID 37871306, PMID 38127722, PMID 38135369, PMID 38551807, PMID 38841802, PMID 39028925, PMID 39047240

NIH funding

U10CA180886 (6), 2016 (5), 2025 (4), 2023 (3), 2014 (2), 2017 (2), P30CA033572 (2), U10CA180820 (2), U10CA180888 (2), 2015 (1), P30CA093373 (1), U10CA021115 (1), U10CA098543 (1), U10CA180821 (1), U24CA196172 (1)